Sonoma Pharmaceuticals, Inc. (SNOA) stock
SNOANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3082% below fair value
$0.83−0.05 (-5.21%)
Close on Nov 17, 2026Market cap $3.99MP/E –Yield –
Sonoma Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Sonoma Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $2.27M, up 17.3% year over year. For fiscal 2026 it was $2.27M, up 25.2% from the year before. Over ten years it grew 2.3% a year on average. The highest annual figure on record is $2.89M in fiscal 2014.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $2.27M | +25.2% |
| FY2025 | Mar 31, 2025 | $1.81M | -3.0% |
| FY2024 | Mar 31, 2024 | $1.87M | +803.9% |
| FY2023 | Mar 31, 2023 | $207.00K | +65.6% |
| FY2022 | Mar 31, 2022 | $125.00K | -77.5% |
| FY2021 | Mar 31, 2021 | $555.00K | -58.6% |
| FY2020 | Mar 31, 2020 | $1.34M | -11.8% |
| FY2019 | Mar 31, 2019 | $1.52M | -3.6% |
| FY2018 | Mar 31, 2018 | $1.58M | -0.1% |
| FY2017 | Mar 31, 2017 | $1.58M | -12.7% |
| FY2016 | Mar 31, 2016 | $1.81M | +17.8% |
| FY2015 | Mar 31, 2015 | $1.53M | -46.9% |
| FY2014 | Mar 31, 2014 | $2.89M | +29.9% |
| FY2013 | Mar 31, 2013 | $2.22M | +12.2% |
| FY2012 | Mar 31, 2012 | $1.98M | -3.2% |
| FY2011 | Mar 31, 2011 | $2.05M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $597.00K | +0.5% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $545.00K | +32.6% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $557.00K | +30.4% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $575.00K | +13.6% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $594.00K | +26.4% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $411.00K | +0.5% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $427.00K | -29.0% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $506.00K | -5.6% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $470.00K | +44.6% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $409.00K | +103.5% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $601.00K | – |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $536.00K | +168.0% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $325.00K | +57.8% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $201.00K | +4925.0% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $0 | -100.0% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $200.00K | +1900.0% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $206.00K | +145.2% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $4.00K | -96.9% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $26.00K | -21.2% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $10.00K | – |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $84.00K | -82.4% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $130.00K | -73.1% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $33.00K | -86.7% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | -$85.00K | -131.5% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $476.00K | +40.8% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $483.00K | +47.7% |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $248.00K | -45.0% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $270.00K | -30.8% |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $338.00K | -3.4% |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $327.00K | -31.3% |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $451.00K | +29.2% |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | $390.00K | +6.0% |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | $350.00K | -8.4% |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | $476.00K | +36.0% |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | $349.00K | -28.3% |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | $368.00K | -2.9% |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | $382.00K | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | $350.00K | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | $487.00K | – |
| Q2 FY2017CQ3 2016 | Sep 30, 2016 | $379.00K | – |
See a number that looks wrong?